1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Advanced Renal Cell Carcinoma Therapeutics Revenue
1.4 Market by Type
1.4.1 Global Advanced Renal Cell Carcinoma Therapeutics Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Radiation Therapy
1.4.3 Chemotherapy
1.4.4 Hormone Therapy
1.4.5 Investigational Therapy
1.5 Market by Application
1.5.1 Global Advanced Renal Cell Carcinoma Therapeutics Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Cancer Research Institutes
1.5.4 Ambulatory Surgical Centers
1.5.5 Others
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Advanced Renal Cell Carcinoma Therapeutics Market Perspective (2015-2026)
2.2 Global Advanced Renal Cell Carcinoma Therapeutics Growth Trends by Regions
2.2.1 Advanced Renal Cell Carcinoma Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Advanced Renal Cell Carcinoma Therapeutics Historic Market Share by Regions (2015-2020)
2.2.3 Advanced Renal Cell Carcinoma Therapeutics Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Advanced Renal Cell Carcinoma Therapeutics Market Growth Strategy
2.3.6 Primary Interviews with Key Advanced Renal Cell Carcinoma Therapeutics Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Advanced Renal Cell Carcinoma Therapeutics Players by Market Size
3.1.1 Global Top Advanced Renal Cell Carcinoma Therapeutics Players by Revenue (2015-2020)
3.1.2 Global Advanced Renal Cell Carcinoma Therapeutics Revenue Market Share by Players (2015-2020)
3.1.3 Global Advanced Renal Cell Carcinoma Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Advanced Renal Cell Carcinoma Therapeutics Market Concentration Ratio
3.2.1 Global Advanced Renal Cell Carcinoma Therapeutics Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Advanced Renal Cell Carcinoma Therapeutics Revenue in 2019
3.3 Advanced Renal Cell Carcinoma Therapeutics Key Players Head office and Area Served
3.4 Key Players Advanced Renal Cell Carcinoma Therapeutics Product Solution and Service
3.5 Date of Enter into Advanced Renal Cell Carcinoma Therapeutics Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Advanced Renal Cell Carcinoma Therapeutics Historic Market Size by Type (2015-2020)
4.2 Global Advanced Renal Cell Carcinoma Therapeutics Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Advanced Renal Cell Carcinoma Therapeutics Market Size by Application (2015-2020)
5.2 Global Advanced Renal Cell Carcinoma Therapeutics Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Advanced Renal Cell Carcinoma Therapeutics Market Size (2015-2020)
6.2 Advanced Renal Cell Carcinoma Therapeutics Key Players in North America (2019-2020)
6.3 North America Advanced Renal Cell Carcinoma Therapeutics Market Size by Type (2015-2020)
6.4 North America Advanced Renal Cell Carcinoma Therapeutics Market Size by Application (2015-2020)
7 Europe
7.1 Europe Advanced Renal Cell Carcinoma Therapeutics Market Size (2015-2020)
7.2 Advanced Renal Cell Carcinoma Therapeutics Key Players in Europe (2019-2020)
7.3 Europe Advanced Renal Cell Carcinoma Therapeutics Market Size by Type (2015-2020)
7.4 Europe Advanced Renal Cell Carcinoma Therapeutics Market Size by Application (2015-2020)
8 China
8.1 China Advanced Renal Cell Carcinoma Therapeutics Market Size (2015-2020)
8.2 Advanced Renal Cell Carcinoma Therapeutics Key Players in China (2019-2020)
8.3 China Advanced Renal Cell Carcinoma Therapeutics Market Size by Type (2015-2020)
8.4 China Advanced Renal Cell Carcinoma Therapeutics Market Size by Application (2015-2020)
9 Japan
9.1 Japan Advanced Renal Cell Carcinoma Therapeutics Market Size (2015-2020)
9.2 Advanced Renal Cell Carcinoma Therapeutics Key Players in Japan (2019-2020)
9.3 Japan Advanced Renal Cell Carcinoma Therapeutics Market Size by Type (2015-2020)
9.4 Japan Advanced Renal Cell Carcinoma Therapeutics Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Advanced Renal Cell Carcinoma Therapeutics Market Size (2015-2020)
10.2 Advanced Renal Cell Carcinoma Therapeutics Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Advanced Renal Cell Carcinoma Therapeutics Market Size by Type (2015-2020)
10.4 Southeast Asia Advanced Renal Cell Carcinoma Therapeutics Market Size by Application (2015-2020)
11 India
11.1 India Advanced Renal Cell Carcinoma Therapeutics Market Size (2015-2020)
11.2 Advanced Renal Cell Carcinoma Therapeutics Key Players in India (2019-2020)
11.3 India Advanced Renal Cell Carcinoma Therapeutics Market Size by Type (2015-2020)
11.4 India Advanced Renal Cell Carcinoma Therapeutics Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Advanced Renal Cell Carcinoma Therapeutics Market Size (2015-2020)
12.2 Advanced Renal Cell Carcinoma Therapeutics Key Players in Central & South America (2019-2020)
12.3 Central & South America Advanced Renal Cell Carcinoma Therapeutics Market Size by Type (2015-2020)
12.4 Central & South America Advanced Renal Cell Carcinoma Therapeutics Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Acceleron Pharma
13.1.1 Acceleron Pharma Company Details
13.1.2 Acceleron Pharma Business Overview
13.1.3 Acceleron Pharma Advanced Renal Cell Carcinoma Therapeutics Introduction
13.1.4 Acceleron Pharma Revenue in Advanced Renal Cell Carcinoma Therapeutics Business (2015-2020))
13.1.5 Acceleron Pharma Recent Development
13.2 Argos Therapeutics
13.2.1 Argos Therapeutics Company Details
13.2.2 Argos Therapeutics Business Overview
13.2.3 Argos Therapeutics Advanced Renal Cell Carcinoma Therapeutics Introduction
13.2.4 Argos Therapeutics Revenue in Advanced Renal Cell Carcinoma Therapeutics Business (2015-2020)
13.2.5 Argos Therapeutics Recent Development
13.3 AVEO Pharmaceuticals
13.3.1 AVEO Pharmaceuticals Company Details
13.3.2 AVEO Pharmaceuticals Business Overview
13.3.3 AVEO Pharmaceuticals Advanced Renal Cell Carcinoma Therapeutics Introduction
13.3.4 AVEO Pharmaceuticals Revenue in Advanced Renal Cell Carcinoma Therapeutics Business (2015-2020)
13.3.5 AVEO Pharmaceuticals Recent Development
13.4 Bayer
13.4.1 Bayer Company Details
13.4.2 Bayer Business Overview
13.4.3 Bayer Advanced Renal Cell Carcinoma Therapeutics Introduction
13.4.4 Bayer Revenue in Advanced Renal Cell Carcinoma Therapeutics Business (2015-2020)
13.4.5 Bayer Recent Development
13.5 Bristol-Myers Squibb Company
13.5.1 Bristol-Myers Squibb Company Company Details
13.5.2 Bristol-Myers Squibb Company Business Overview
13.5.3 Bristol-Myers Squibb Company Advanced Renal Cell Carcinoma Therapeutics Introduction
13.5.4 Bristol-Myers Squibb Company Revenue in Advanced Renal Cell Carcinoma Therapeutics Business (2015-2020)
13.5.5 Bristol-Myers Squibb Company Recent Development
13.6 Eisai
13.6.1 Eisai Company Details
13.6.2 Eisai Business Overview
13.6.3 Eisai Advanced Renal Cell Carcinoma Therapeutics Introduction
13.6.4 Eisai Revenue in Advanced Renal Cell Carcinoma Therapeutics Business (2015-2020)
13.6.5 Eisai Recent Development
13.7 Exelixi
13.7.1 Exelixi Company Details
13.7.2 Exelixi Business Overview
13.7.3 Exelixi Advanced Renal Cell Carcinoma Therapeutics Introduction
13.7.4 Exelixi Revenue in Advanced Renal Cell Carcinoma Therapeutics Business (2015-2020)
13.7.5 Exelixi Recent Development
13.8 Genentech
13.8.1 Genentech Company Details
13.8.2 Genentech Business Overview
13.8.3 Genentech Advanced Renal Cell Carcinoma Therapeutics Introduction
13.8.4 Genentech Revenue in Advanced Renal Cell Carcinoma Therapeutics Business (2015-2020)
13.8.5 Genentech Recent Development
13.9 Immatics Biotechnologies
13.9.1 Immatics Biotechnologies Company Details
13.9.2 Immatics Biotechnologies Business Overview
13.9.3 Immatics Biotechnologies Advanced Renal Cell Carcinoma Therapeutics Introduction
13.9.4 Immatics Biotechnologies Revenue in Advanced Renal Cell Carcinoma Therapeutics Business (2015-2020)
13.9.5 Immatics Biotechnologies Recent Development
13.10 Merck
13.10.1 Merck Company Details
13.10.2 Merck Business Overview
13.10.3 Merck Advanced Renal Cell Carcinoma Therapeutics Introduction
13.10.4 Merck Revenue in Advanced Renal Cell Carcinoma Therapeutics Business (2015-2020)
13.10.5 Merck Recent Development
13.11 Novartis
10.11.1 Novartis Company Details
10.11.2 Novartis Business Overview
10.11.3 Novartis Advanced Renal Cell Carcinoma Therapeutics Introduction
10.11.4 Novartis Revenue in Advanced Renal Cell Carcinoma Therapeutics Business (2015-2020)
10.11.5 Novartis Recent Development
13.12 Ono Pharmaceutical
10.12.1 Ono Pharmaceutical Company Details
10.12.2 Ono Pharmaceutical Business Overview
10.12.3 Ono Pharmaceutical Advanced Renal Cell Carcinoma Therapeutics Introduction
10.12.4 Ono Pharmaceutical Revenue in Advanced Renal Cell Carcinoma Therapeutics Business (2015-2020)
10.12.5 Ono Pharmaceutical Recent Development
13.13 Pfizer
10.13.1 Pfizer Company Details
10.13.2 Pfizer Business Overview
10.13.3 Pfizer Advanced Renal Cell Carcinoma Therapeutics Introduction
10.13.4 Pfizer Revenue in Advanced Renal Cell Carcinoma Therapeutics Business (2015-2020)
10.13.5 Pfizer Recent Development
13.14 Rexahn Pharmaceuticals
10.14.1 Rexahn Pharmaceuticals Company Details
10.14.2 Rexahn Pharmaceuticals Business Overview
10.14.3 Rexahn Pharmaceuticals Advanced Renal Cell Carcinoma Therapeutics Introduction
10.14.4 Rexahn Pharmaceuticals Revenue in Advanced Renal Cell Carcinoma Therapeutics Business (2015-2020)
10.14.5 Rexahn Pharmaceuticals Recent Development
13.15 Hoffmann-La Roche
10.15.1 Hoffmann-La Roche Company Details
10.15.2 Hoffmann-La Roche Business Overview
10.15.3 Hoffmann-La Roche Advanced Renal Cell Carcinoma Therapeutics Introduction
10.15.4 Hoffmann-La Roche Revenue in Advanced Renal Cell Carcinoma Therapeutics Business (2015-2020)
10.15.5 Hoffmann-La Roche Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
【掲載企業】
Acceleron Pharma、Argos Therapeutics、AVEO Pharmaceuticals、Bayer、Bristol-Myers Squibb Company、Eisai、Exelixi、Genentech、Immatics Biotechnologies、Merck、Novartis、Ono Pharmaceutical、Pfizer、Rexahn Pharmaceuticals、Hoffmann-La Roche
【免責事項】
https://www.globalresearch.jp/disclaimer